Get started
Author

Irene Straßl

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
2024 · Elena Zamagni, Tobias Silzle, et al. · Blood · 33
PDF
HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation
2017 · Johannes Clausen, Alexandra Böhm, et al. · Biomedicines · 13
PDF
The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond
2021 · Irene Strassl, Martin Schreder, et al. · Cancers · 10
PDF
Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR)
2023 · Magdalena A. Benda, Hanno Ulmer, et al. · Cancers · 9
PDF
Successful SARS-CoV-2 mRNA Vaccination Program in Allogeneic Hematopoietic Stem Cell Transplant Recipients—A Retrospective Single-Center Analysis
2023 · Alexander Nikoloudis, Ines Julia Neumann, et al. · Vaccines · 8
PDF
The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma
2024 · Irene Strassl, Klaus Podar · Expert Opinion on Drug Discovery · 7
Relapse Protection Following Early Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation Is Limited to HLA-C Killer Cell Immunoglobulin-Like Receptor Ligand Homozygous Recipients
2021 · Alexander Nikoloudis, Helga Wagner, et al. · Transplantation and Cellular Therapy · 7
Impact of the Recipient’s Pre-Treatment Blood Lymphocyte Count on Intended and Unintended Effects of Anti-T-Lymphocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation
2023 · Alexander Nikoloudis, Veronika Buxhofer-Ausch, et al. · Cells · 6
PDF
Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis
2024 · Sigrid Machherndl-Spandl, Sarah Hannouf, et al. · Cancers · 5
PDF
Impact of early cyclosporine A levels on acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation using in vivo T-cell depletion
2024 · Alexander Nikoloudis, Veronika Buxhofer-Ausch, et al. · Cytotherapy · 5
PDF
Adverse impact of a high CD4 / CD8 ratio in the allograft may be overcome by methotrexate‐ but not mycophenolate‐ or post‐transplant cyclophosphamide‐based graft versus host disease prophylaxis
2023 · A. Nikoloudis, V. Buxhofer‐Ausch, et al. · European Journal Of Haematology · 5
PDF
TOP-PIC: a new tool to optimize pharmacotherapy and reduce polypharmacy in patients with incurable cancer
2023 · Irene Strassl, Armin Windhager, et al. · Journal of Cancer Research and Clinical Oncology · 4
PDF
Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options—A Single-Center Experience
2023 · Irene Strassl, Alexander Nikoloudis, et al. · Cancers · 3
PDF
Comparison of Benefits and Risks Associated with Anti-T-Lymphocyte Globulin (ATLG) Serotherapy in Methotrexate (MTX)- versus Mycophenolate Mofetil (MMF)-Based Hematopoietic Stem Cell Transplantation
2023 · Alexander Nikoloudis, Irene Strassl, et al. · Transplantology · 3
PDF
Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
2026 · Maximilian Merz, Tomas Jelinek, et al. · Blood Cancer Discovery · 2
Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
2026 · Ashutosh D. Wechalekar, Angela Dispenzieri, et al. · Journal of Clinical Oncology · 2
Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma
2026 · Leo Rasche, Maria Theresa Krauth, et al. · Bone Marrow Transplantation · 2
PDF
The impact of tacrolimus levels on acute GVHD and transplant outcomes in haploidentical hematopoietic stem cell transplantation: A retrospective analysis
2025 · Alexander Nikoloudis, Veronika Buxhofer-Ausch, et al. · Cell Transplantation · 2
Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Prolymphocytic Leukemia
2025 · Christina Groiss, Stefanie Kreissl, et al. · Journal of Clinical Medicine · 2
PDF
Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review
2026 · Magdalena Benda, Patrick Reimann, et al. · Annals of Hematology · 1
Rapid Hematological and Molecular Response to Pegylated Interferon in WHO-Defined Pre-Fibrotic Myelofibrosis
2025 · Sigrid Machherndl-Spandl, Marcel Kiehberger, et al. · Cancers · 1
PDF
Implementation of a one‐tube flow cytometry panel for measurable residual disease detection in multiple myeloma patients in clinical routine
2025 · Karin Deutsch‐Biedermann, Katrin Hefler‐Frischmuth, et al. · Cytometry Part B Clinical Cytometry · 1
PDF
P09: Attrition Rates in Multiple Myeloma Under Real World Conditions – an Analysis From the Austrian Myeloma Registry
2022 · MA Benda, H Ulmer, et al. · HemaSphere · 1
Supplementary Table S3 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
2026 · Maximilian Merz, Tomas Jelinek, et al.
Data from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
2026 · Maximilian Merz, Tomas Jelinek, et al.
Works count: 53
Citation count: 132
H-index: 7
I10-index: 3
Year
Topic
Type